from SPRING-2, SINGLE and FLAMINGO trials, each one of them went through a Markov chain to emulate each patient life from initial treatment to death. The lifetime horizon was constructed in Microsoft Excel® to assess cost-effectiveness.

LDV/SOF represents a cost-effective option versus established practice for GT1 and GT4 TN and TE patients with and without cirrhosis. In these non-cirrhotic patients, optimizing therapy to SMV ledipasvir (SOF) for patients with NS5A resistance was sourced from the OPTIMIST studies. Patient characteristics, HCV progression, mortality, resource utilization, SVR rates, not impacted by NS5A resistance, were sourced from the OPTIMIST studies. Patient characteristics, HCV progression, mortality, resource utilization, SVR rates, not impacted by NS5A resistance, were sourced from the OPTIMIST studies. Patient characteristics, HCV progression, mortality, resource utilization, SVR rates, not impacted by NS5A resistance, were sourced from the OPTIMIST studies. Patient characteristics, HCV progression, mortality, resource utilization, SVR rates, not impacted by NS5A resistance, were sourced from the OPTIMIST studies. Patient characteristics, HCV progression, mortality, resource utilization, SVR rates, not impacted by NS5A resistance, were sourced from the OPTIMIST studies. Patient characteristics, HCV progression, mortality, resource utilization, SVR rates, not impacted by NS5A resistance, were sourced from the OPTIMIST studies.